Все публикации

0:03:39

Fueling dementia policy change on an international level

0:08:11

The spread of oligomeric tau through synapses in Alzheimer's disease

0:01:37

The impact of meditation on mental health and well-being in aging

0:02:18

The potential of brain-derived tau as a neurodegeneration biomarker

0:03:05

Sex differences in Alzheimer's disease plasma biomarkers

0:02:27

Polygenic risk scores for Alzheimer's disease in relation to cognitive change

0:01:46

Next steps in anti-amyloid immunotherapy

0:04:48

Subtyping mixed primary progressive aphasia

0:01:13

Neuroprotective effects of transcription factor NRF2 in Alzheimer’s disease mice models

0:01:12

ALZ-801 in combination with anti-amyloid antibodies for the treatment of Alzheimer’s disease

0:01:45

Promise of tau-PET imaging for Alzheimer's disease

0:01:34

Prognostic value of plasma biomarkers GFAP and pTau181 for all-cause and Alzheimer’s dementia

0:05:19

Examining plasma vs. CSF p-tau217 in preclinical and prodromal Alzheimer’s disease

0:01:15

Evolving use of tau-specific fluid biomarkers for Alzheimer's disease

0:03:31

ALZ-801 Phase II data & launch of Phase III study in early Alzheimer’s disease

0:04:19

Current projects from Alzheimer’s Disease International

0:01:24

Digital frailty screening in dementia

0:00:50

Will long-term anti-amyloid treatment show greater clinical benefit?

0:02:33

Anti-amyloid therapy for Alzheimer's disease: beyond the 18-month mark

0:04:44

Influence of genetic risk for psychiatric disorders on dementia

0:04:12

Updates in Alzheimer’s treatment: the potential of NSC001

0:02:06

The role of governments in addressing the access issues to dementia treatment

0:02:31

Barriers to dementia treatment: awareness, accessibility, and affordability

0:02:06

The potential of ALZ-801 as an oral small molecule treatment for Alzheimer’s disease